Display options
Cite
Walden P, Jiang Q, Jackson EA, et al. Assessing the incremental benefit of an extended duration lifestyle intervention for the components of the metabolic syndrome. Diabetes Metab Syndr Obes. 2016;9:177-84doi: 10.2147/DMSO.S94772.
Walden, P., Jiang, Q., Jackson, E. A., Oral, E. A., Weintraub, M. S., & Rubenfire, M. (2016). Assessing the incremental benefit of an extended duration lifestyle intervention for the components of the metabolic syndrome. Diabetes, metabolic syndrome and obesity : targets and therapy, 9177-84. https://doi.org/10.2147/DMSO.S94772
Walden, Patrick, et al. "Assessing the incremental benefit of an extended duration lifestyle intervention for the components of the metabolic syndrome." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 9 (2016): 177-84. doi: https://doi.org/10.2147/DMSO.S94772
Walden P, Jiang Q, Jackson EA, Oral EA, Weintraub MS, Rubenfire M. Assessing the incremental benefit of an extended duration lifestyle intervention for the components of the metabolic syndrome. Diabetes Metab Syndr Obes. 2016 Jun 01;9:177-84. doi: 10.2147/DMSO.S94772. eCollection 2016. PMID: 27330320; PMCID: PMC4898037.
Copy Download .nbib Format: NLM
Share it on

Diabetes Metab Syndr Obes. 2016 Jun 01;9:177-84. doi: 10.2147/DMSO.S94772. eCollection 2016.

Assessing the incremental benefit of an extended duration lifestyle intervention for the components of the metabolic syndrome.

Diabetes, metabolic syndrome and obesity : targets and therapy

Patrick Walden, Qingmei Jiang, Elizabeth A Jackson, Elif A Oral, Martha S Weintraub, Melvyn Rubenfire

Affiliations

  1. Division of Cardiovascular Medicine, Cardiovascular Medicine at Domino's Farms, University of Michigan Health System, Ann Arbor, MI, USA.

PMID: 27330320 PMCID: PMC4898037 DOI: 10.2147/DMSO.S94772

Abstract

BACKGROUND: Lifestyle interventions targeting the components of the metabolic syndrome (MetSyn) have been demonstrated to be a cost-effective and suitable treatment strategy for reducing one's risk of developing coronary artery disease and diabetes. The optimal duration has not yet been defined. We sought to evaluate the incremental benefit of extending a lifestyle intervention from 3 months to 6 months.

METHODS: We evaluated 114 participants with at least three criteria for the MetSyn in a physician-referred 6-month lifestyle intervention between August 2008 and December 2012. Baseline and follow-up physiological, biochemical, and anthropometric data were analyzed for mean change and incremental change at each time point.

RESULTS: The mean age at enrollment was 53.0±10.2 years, and 42% of participants were males. The mean body mass index at enrollment was 38.2±0.86 kg/m(2) for males and 38.6±0.93 kg/m(2) for females. Anthropometric measures associated with weight management (body mass index, weight, and body fat percentage) improved significantly with the additional 3-month intervention (P<0.001). Systolic blood pressure (P=0.0001) and diastolic blood pressure (P=0.00006) and triglycerides, fasting blood glucose, and homeostatic model assessment of insulin resistance in diabetic participants (P=0.006, P=0.004, P=0.01, respectively) improved rapidly in the initial 3-month intervention without incremental benefit of the additional 3 months. Improvements in fasting insulin (P=0.01) and homeostatic model assessment of insulin resistance (P=0.02) for nondiabetic participants required the full 6-month intervention before significant reductions were achieved.

CONCLUSION: A 6-month lifestyle intervention yielded significantly better results for variables related to weight management. Standard physiological measures for the MetSyn respond rapidly in a 3-month lifestyle intervention. The long-term impact of an increased duration lifestyle intervention remains to be seen.

Keywords: diabetes; lifestyle intervention; metabolic syndrome

References

  1. J Am Coll Cardiol. 1997 Jul;30(1):260-311 - PubMed
  2. J Gen Intern Med. 2001 Sep;16(9):606-13 - PubMed
  3. J Cardiopulm Rehabil Prev. 2011 Sep-Oct;31(5):282-9 - PubMed
  4. J Am Coll Cardiol. 2013 Aug 20;62(8):697-703 - PubMed
  5. Am J Clin Nutr. 1990 Feb;51(2):241-7 - PubMed
  6. Open J Prev Med. 2013 Dec 9;3(9):526-533 - PubMed
  7. Am J Prev Med. 2008 Oct;35(4):357-63 - PubMed
  8. J Am Coll Cardiol. 2010 Sep 28;56(14):1113-32 - PubMed
  9. Diabetes Care. 2008 Sep;31(9):1898-904 - PubMed
  10. Vascul Pharmacol. 2012 Nov-Dec;57(5-6):133-8 - PubMed
  11. J Cardiopulm Rehabil Prev. 2013 Nov-Dec;33(6):360-70 - PubMed
  12. BMJ. 2007 Feb 10;334(7588):299 - PubMed
  13. Diabetes Care. 2014 Feb;37(2):555-64 - PubMed
  14. Eur J Clin Nutr. 2004 Nov;58(11):1550-2 - PubMed
  15. J Am Coll Cardiol. 2007 Jan 30;49(4):403-14 - PubMed
  16. Prev Med. 2010 Jul;51(1):11-7 - PubMed
  17. N Engl J Med. 2002 Feb 7;346(6):393-403 - PubMed
  18. Cochrane Database Syst Rev. 2010 Jul 07;(7):CD007131 - PubMed
  19. J Am Coll Cardiol. 2014 Apr 15;63(14):1345-54 - PubMed

Publication Types

Grant support